



CONSCIOUSNESS UNDER PRESSURE

*Hallucinogens and Mixed Delusions — How Chemistry and Belief
Can Bend the Mind's Mirror*

Akmal , Medical Student, Samarkand State Medical University,
Uzbekistan

Abishek Lingam D.K , Medical Student, Samarkand State Medical University,
Uzbekistan

Aadil khan , Medical Student, Samarkand State Medical University, Uzbekistan

Areeb khan , Medical Student, Samarkand State Medical University, Uzbekistan

Abstract

Consciousness is the one thing each of us knows with absolute certainty — and the one thing science has the hardest time explaining. It is also fragile. Certain molecules, taken deliberately or by accident, can rearrange it within minutes; certain illnesses can entrench false beliefs so stubbornly that no argument can dislodge them. This article tells the story of two ways the mind's grip on reality can loosen: hallucinogens, the classic psychedelic compounds now undergoing a remarkable clinical renaissance, and mixed delusions, the clinically common but under-discussed condition in which a person harbours two or more delusional themes at once. Written in narrative form, the article traces what consciousness is, how drugs such as psilocybin and LSD alter it, what delusions are and why the “mixed” subtype matters, and where these two territories — one voluntary and temporary, one involuntary and persistent — unexpectedly overlap.

1. The Strangest Thing You Own

Right now, as you read this sentence, something extraordinary is happening inside your skull. Light patterns strike your retinas, sound waves press against your eardrums, and within fractions of a second these physical events are transformed into a private, inner world: the smell of coffee, the feeling of the chair beneath you, the very sense that you are someone having an experience. That transformation — from electrochemistry to inner life — is consciousness, and philosophers have been



tripping over it for millennia. The physicist Arthur Eddington remarked nearly a century ago that if we want to understand the universe, we should perhaps start with the one piece of it we know from the inside.

Consciousness is also, for all its mystery, surprisingly easy to perturb. A night of missed sleep blurs it; a fever distorts it; a blow to the head extinguishes it. And certain molecules — a class of compounds we call hallucinogens — can disassemble and reassemble it in the space of an hour, producing experiences that subjects describe as among the most meaningful of their lives, or among the most terrifying. Meanwhile, at the opposite end of the spectrum from voluntary chemical exploration, there are people whose consciousness has not been opened but narrowed: people gripped by fixed, false beliefs known as delusions, which in the “mixed” form arrive not as one coherent story but as several incompatible ones braided together. Understanding both phenomena — and how they differ — is the work of this article.

2. What Consciousness Actually Is

Clinicians and neuroscientists usually split consciousness into two ingredients. The first is wakefulness — the basic level of alertness running from deep anaesthesia through dreamless sleep to full attention, largely managed by the brainstem and thalamus. The second, richer ingredient is awareness: the content of experience, the “what it is like” of seeing red or feeling sad. A person in a dream is asleep (low wakefulness) yet vividly aware. A patient in a vegetative state may open their eyes (preserved wakefulness) while awareness is absent. Much of the brain's busiest wiring — including a constellation of regions called the default mode network, active when we daydream, remember, and construct our sense of self — appears to act as the stage on which awareness plays.

This framework matters because hallucinogens and delusions attack consciousness differently. Hallucinogens broadly preserve wakefulness while flooding awareness with novel, disorganised content — the world remains vivid, but its rules seem suspended. Delusions, by contrast, leave perception largely intact while corrupting the beliefs woven from it: the world looks the same, but its meaning has been rewritten. One alters the raw material of experience; the other alters the conclusions drawn from it. Holding that distinction clearly will matter in everything that follows.



Figure 1. Artistic rendering of the human brain's connective architecture — the physical substrate of consciousness that both hallucinogens and delusional disorders leave visible on a scanner yet profoundly change in experience.

3. Hallucinogens: Chemistry That Dissolves the Self

The classic hallucinogens — LSD, psilocybin, mescaline, and DMT — are united by a surprisingly specific talent: they mimic serotonin, one of the brain's principal chemical messengers, at a particular receptor called 5-HT_{2A}. When these molecules occupy that receptor in the cortex, the brain's normally tidy traffic of prediction and perception loosens. Regions that usually exchange information along fixed highways begin to crosstalk. The default mode network, which neuroscientists suspect helps construct the sense of a continuous self — the “I” that remembers yesterday and plans tomorrow — shows reduced coordination. The result, in the memorable phrasing of one research group, is that the brain becomes “hyperconnected”: its segregated networks talk to one another as they rarely do in ordinary life.

Subjective reports match the scans eerily well. Boundaries soften: the wall between self and world, between listener and music, between present moment and distant memory. Synaesthesias bloom — people hear colours or see sounds. Time stretches or vanishes. And a substantial share of volunteers in modern studies describe the experience as among the most spiritually significant of their lives — a statistic that has moved hallucinogens from the counterculture into the clinic with astonishing



speed. The same chemistry, of course, explains the compounds' dangers: in an uncontrolled setting, with an anxious or predisposed mind, the loosened grip on reality can tip into terror — the infamous “bad trip” — and in vulnerable individuals, into lasting problems.

Compound	Natural source / origin	Primary target	Typical duration	Research status (2026)
Psilocybin	Psilocybe “magic” mushrooms	Serotonin 5-HT2A agonist (prodrug)	4–6 hours	Phase 2–3 trials for depression; therapy programmes authorised in parts of Australia and the U.S.
LSD	Synthesised (ergot alkaloid chemistry)	Serotonin 5-HT2A agonist	8–12 hours	Trials for anxiety and addiction; microdosing studies ongoing
DMT	Plants (e.g., Psychotria, Mimosa); trace endogenous	Serotonin 5-HT2A agonist	15–60 minutes (smoked)	Early-phase depression trials; studied as ayahuasca with MAOIs
Mescaline	Peyote and San Pedro cacti	Serotonin 5-HT2A ($\pm$ others)	10–14 hours	Limited clinical data; mostly historical and survey research
MDMA*	Synthesised	Serotonin release +	3–6 hours	Phase 3 PTSD trials;



		receptor effects		regulatory decisions pending
--	--	---------------------	--	------------------------------------

*Table 1. Principal classic hallucinogens and their clinical-research status.
(*MDMA is technically an empathogen rather than a classic hallucinogen but
shares the therapeutic-research wave.)*




Figure 2. fMRI studies of psilocybin show consistent decreases in blood flow and connectivity in hub regions — a neural signature of the “dissolved self” reported by volunteers (Carhart-Harris et al., PNAS, 2012).

4. The Clinical Renaissance

For roughly thirty years, research on these compounds was frozen — a casualty of the mid-twentieth-century war on drugs. Then, cautiously, around the turn of the millennium, licences were granted, ethics boards convened, and a new generation of studies began. The results have been striking enough to keep the funding flowing. In randomised trials, psilocybin-assisted psychotherapy has produced rapid, large reductions in depression scores in patients who had failed multiple conventional



treatments; MDMA-assisted therapy has shown strong effects in post-traumatic stress disorder; and cancer patients facing death have reported lasting reductions in existential anxiety after a single supported session.

Crucially, the modern model is nothing like recreational use. It is a structured choreography of three acts: preparation, in which the patient builds trust with trained therapists and sets an intention; the dosing session itself, in a comfortable room with eyeshades and curated music, with therapists present but mostly silent; and integration, the weeks afterwards in which the experience is unpacked and woven into ordinary life. The drug, in this framing, is less a treatment than an amplifier — something that makes psychotherapy deeper, faster, and more durable. Whether that framing survives the largest and most rigorous trials now underway remains an open question; the field's own methodologists have warned loudly about expectancy effects, broken blinding, and small samples. The honest summary: the signal is promising, the mechanisms are plausible, and the verdict is not yet final.

Stages of Psychedelic Therapy




Figure 3. The three-stage architecture of modern psychedelic-assisted therapy: preparation, dosing, and integration (adapted from methodological guidance for clinical trials).

5. Delusions: Beliefs That Refuse to Die



Now shift scenes, from the temporary dissolution of the self to its opposite error: certainty without evidence. A delusion is conventionally defined by psychiatrists as a fixed, false belief — one held with remarkable conviction, impervious to contradictory argument or plain proof, and not explained by the person's culture or upbringing. The qualifier “fixed” does most of the clinical work.

Ordinary wrong beliefs bend under evidence; delusions do not. A patient shown clear bank statements may still insist that a hidden organisation is draining his account; a woman whose partner has never been out of her sight may remain convinced of his infidelity; a man examined repeatedly by dermatologists may continue to feel parasites crawling beneath intact skin.

Classically, delusional disorder is catalogued by theme. The erotomaniac type holds that someone — often a stranger of higher status — is secretly in love with them. The grandiose type harbours inflated beliefs about power, genius, or identity. The jealous type constructs unfaithfulness from nothing. The persecutory type, the most common in clinical practice, spins plots of surveillance, poisoning, and harm. The somatic type locates the catastrophe in the body: infestation, deformity, foul odour, failing organs. And then there is the type that concerns us most here: the mixed type, in which two or more themes coexist without any single one dominating.

Subtype	Core false belief	How it may look in daily life
Erotomaniac	“This person is in love with me”	Fixation on a celebrity, boss, or stranger; repeated unwanted contact attempts
Grandiose	“I have a great gift, power, or destiny”	Claims of secret inventions, special missions, or royal identity
Jealous	“My partner is unfaithful”	Endless checking of phones, searches for evidence, accusations
Persecutory	“I am being watched, harmed, or conspired against”	Complaints to authorities, barricading doors, deep mistrust of doctors



Somatic	“My body is diseased, infested, or defective”	Doctor-shopping, skin examinations, demands for surgery
Mixed	Two or more themes, none predominant	A shifting mosaic — persecutory one month, grandiose the next

Table 2. Thematic subtypes of delusional disorder, per DSM-5-TR classification. The mixed type (highlighted) is the focus of this article.

6. Mixed Delusions: The Clinical Mosaic

Pure, single-theme delusional disorder makes tidy textbook reading; mixed delusions make real clinics. In the mixed type, the patient carries several delusional themes at once, and the balance among them can drift over time. A woman may simultaneously believe that her neighbours are poisoning her water (persecutory), that she alone has discovered the cure for cancer (grandiose), and that a surgeon she met once is secretly devoted to her (erotomantic). Nothing in this constellation is bizarre enough to be obviously impossible, which is precisely what makes mixed delusions so clinically slippery: each strand is woven from plausible fabric, and together they form a private narrative that can hold together for years.

The mixed type also illustrates something important about how delusions behave. They are not random noise; they are attempts — pathological ones — at meaning-making. The mind, confronted with coincidence, ambiguity, and anxiety, builds explanations, and in the delusional mind the normal brakes on that construction process fail. Neurobiologically, delusions are increasingly understood as disorders of prediction: the brain's machinery for weighing evidence against prior belief tips too far toward belief, so that everything confirms the story and nothing disconfirms it. Notably, the same predictive-machinery account has been invoked to explain hallucinogen effects — the difference being that the drug's distortion is pharmacological, temporary, and (in a therapeutic setting) held safely, while the delusional distortion is entrenched, self-sustaining, and often invisible to the person living inside it.



This is why clinicians screen so carefully before psychedelic-assisted therapy: a personal or family history of psychotic-spectrum illness is generally an exclusion criterion, because a compound that loosens the mind's grip on reality must never be offered to a mind already struggling to hold it.

Feature	Hallucinogen intoxication	Mixed delusional disorder
Onset	Minutes to hours after dosing	Insidious; often months of gradual conviction
Insight	Usually preserved (“this is the drug”)	Absent; the beliefs feel like facts
Duration	Hours; resolves as drug clears	At least 1 month; often chronic
Belief structure	Fluid, shifting, often mystical	Fixed themes; internally woven narrative
Perception vs. belief	Perception vividly altered	Perception largely intact; interpretation corrupted
Course	Self-limited	Requires treatment; fluctuates with stress
Typical treatment	Reassurance, “talking down”, supportive care	Antipsychotics, psychotherapy, sometimes long-term care

Table 3. A clinician's-eye comparison: the voluntary, temporary alteration of hallucinogen intoxication versus the involuntary, persistent alteration of mixed delusional disorder.

7. Where the Two Territories Meet

Voluntary and involuntary alterations of consciousness meet in a few uneasy borderlands. Substance-induced psychotic disorder is the most direct: heavy or prolonged hallucinogen use can, in a minority of users, trigger psychotic episodes that outlast the drug itself — weeks or months of delusions and hallucinations that earn their own diagnosis. A related but rarer condition, hallucinogen persisting perception disorder (HPPD), leaves visual disturbances — trailing lights, visual snow, geometric overlays — lingering for months or years after the last dose. Then



there is the subtler question researchers are only beginning to study: whether the mystical-type experiences that make psychedelic therapy effective bear any family resemblance to the conviction-certainty of delusion. Both involve powerful meaning-making; one arrives with an intact witness who knows the experience will end, the other without. The difference, clinicians insist, is everything.

History adds a cautionary footnote. The optimism of the 1950s and 60s — when LSD was briefly hailed as a psychiatric miracle — collapsed under recreational excess, legal prohibition, and a research freeze that cost science decades. Today's renaissance is deliberately more disciplined: registered trials, blinded designs where possible, trained therapists, exclusion criteria, and integration protocols. Whether that discipline is enough will be decided by the large phase 3 programmes whose results are due within this decade.

8. Hard Questions on Both Fronts

Neither territory is free of ethical weight. For hallucinogens: Who should receive them, and who screens the screeners? What does informed consent mean for a compound that can produce experiences patients describe as beyond words? Can blinding ever really hold when the drug announces itself unmistakably? And how do societies regulate a therapy whose most potent ingredient may be the quality of the human relationship surrounding the dose? For delusional disorders: how do clinicians honour a person's autonomy when that person's map of reality is distorted — persuasion rarely works, coercion damages trust, and yet untreated delusions can ruin marriages, careers, and sometimes lives? The mixed form compounds the difficulty, because its shifting themes can evade the neat diagnostic categories on which treatment pathways depend.

And beneath both fields lies the oldest question of all: what consciousness is for, and what it costs to keep it stable. The hallucinogen literature suggests that loosening the self, briefly and safely, can sometimes heal it. The delusion literature shows what happens when the self's story hardens past the reach of evidence. Between dissolution and rigidity lies the narrow, workable middle ground we call sanity — a condition neither guaranteed nor fully understood, and worth defending with both chemistry and compassion.

9. Conclusion: The Narrow Ledge Between Dissolution and Rigidity



Consciousness, this article has argued, is best understood not as a single light switched on or off, but as a delicate negotiation between wakefulness and awareness, between incoming evidence and prior belief. Hallucinogens and mixed delusions disturb that negotiation from opposite directions. The first floods awareness with novelty while leaving the witness intact, and — in careful clinical hands — may turn that flood into healing. The second corrupts belief itself, so that the witness vanishes into the story, and healing requires patiently rebuilding the capacity to doubt.

The two phenomena may never share a treatment, but they share a lesson: the mind's grip on reality is neither a lock nor a given. It is a skill — practised, fragile, and improvable. The scientists mapping serotonin receptors in fMRI machines and the psychiatrists sitting with patients who believe they are poisoned are working on the same mystery from two sides. Somewhere between the scan and the consulting room lies the answer to how a kilogramme of tissue generates a world — and how to help when that world goes wrong.



Figure 4. A patient in a supported psilocybin session — eyeshades on, music playing, therapists nearby: the carefully staged setting that distinguishes modern therapy from recreational use (Johns Hopkins Medicine).

References

- Carhart-Harris, R.L., et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. PNAS, 2012.
- Carhart-Harris, R.L., et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports, 2017.



Cleveland Clinic. Delusional Disorder: Causes, Symptoms, Types & Treatment, 2022.

Medscape (Kiran, C., Chaudhury, S.). Delusional Disorder: Overview, Diagnostic Criteria, Epidemiology, 2026.

- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed., Text Revision (DSM-5-TR), 2022.
- Freudenmann, R.W., & Olajide, D. Psychosis. Continuum (Minneapolis, Minn.), 2015 (PMC).
- Mills, S., et al. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology, 2023.
- Johns Hopkins Medicine. Psychedelic treatment with psilocybin relieves major depression, study shows, 2020.
- Berkeley Center for the Science of Psychedelics. Clinical Trials Map (ClinicalTrials.gov data), accessed 2026.
- Schenberg, E.E. From Efficacy to Effectiveness: Evaluating Psychedelic Clinical Trials. PMC, 2025.